Baird Financial Group
BBIO icon

Baird Financial Group’s BridgeBio Pharma BBIO Stock Holding History

Baird Financial Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.88M Sell
38,672
-1,859
-5% -$130K ﹤0.01% 965
2026
Q1 		$3.01M Sell
40,531
-279
-0.7% -$20.2K ﹤0.01% 906
2025
Q4 		$3.12M Sell
40,810
-16,785
-29% -$1.1M ﹤0.01% 900
2025
Q3 		$2.99M Buy
57,595
+15,538
+37% +$758K ﹤0.01% 911
2025
Q2 		$1.82M Buy
42,057
+731
+2% +$26.6K ﹤0.01% 1039
2025
Q1 		$1.43M Buy
+41,326
New +$1.39M ﹤0.01% 1072

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Baird Financial Group's BBIO Position: Q2 2026 in Review

Baird Financial Group reduced its BridgeBio Pharma (BBIO) stake by 4.6% in Q2 2026, selling an estimated $130K and leaving 38,672 shares worth $2.88M. The position accounts for ﹤0.01% of the portfolio, ranked #965.

Baird Financial Group first reported a position in BBIO in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.12M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Baird Financial Group held 38,672 shares of BridgeBio Pharma worth $2.88M as of Q2 2026.
  • Baird Financial Group sold 1,859 BridgeBio Pharma shares in Q2 2026, an estimated $130K.
  • BridgeBio Pharma made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #965 holding.
  • Baird Financial Group first reported a position in BridgeBio Pharma in Q1 2025 and has held it in 6 quarters since.
  • Baird Financial Group's BridgeBio Pharma position peaked at $3.12M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.